Influvac S

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic, the active ingredient in Influvac S, is an influenza vaccine presented as an injectable formulation for intramuscular or subcutaneous use. It is intended to prevent influenza infection caused by influenza A and B viruses in individuals aged six months and older.

GNH USA supplies Influvac S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution.

Influvac S is an influenza vaccine used to prevent seasonal influenza caused by influenza A and B viruses.

Seasonal influenza: reduces the risk of laboratory‑confirmed influenza infection in the general population. High‑risk groups (e.g., elderly, young children, chronic disease patients): provides enhanced protection against severe disease and complications. Pandemic preparedness: contributes to herd immunity and supports public health strategies during influenza outbreaks.

Like other injectable influenza vaccines, Influvac S may be associated with local and systemic reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: transient erythema or edema around the injection area. - Low‑grade fever: temperature rise up to 38 °C within 24 hours. - Headache: mild headache lasting a day or two. - Muscle aches: transient myalgia.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare demyelinating neuropathy reported post‑vaccination. - Seizures: uncommon febrile seizures in young children. - Thrombotic events: very rare clotting disorders.

Before administering Influvac S, healthcare professionals should consider the following precautions. - Allergy assessment: avoid use in individuals with known hypersensitivity to any vaccine component. - Fever or acute illness: defer vaccination until recovery. - Previous vaccine reaction: evaluate risk if a severe reaction occurred after a prior influenza vaccine. - Pregnancy and lactation: discuss benefits and risks with the prescriber; data are limited. - Storage at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Influvac S may interact with other agents, although vaccine‑specific drug interactions are uncommon.

Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration within 4 weeks to prevent interference with immune response. - Immunoglobulin therapy: postpone vaccination for at least 3 months after receipt of immune globulin. - High‑dose immunosuppressive therapy: avoid during intense corticosteroid treatment as response may be reduced.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): may reduce antibody response if taken prophylactically; use for symptom relief only after vaccination. - Antiviral drugs (oseltamivir): generally safe but monitor for any alteration in vaccine efficacy.